EP1791562A4 - Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine - Google Patents

Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine

Info

Publication number
EP1791562A4
EP1791562A4 EP05812510A EP05812510A EP1791562A4 EP 1791562 A4 EP1791562 A4 EP 1791562A4 EP 05812510 A EP05812510 A EP 05812510A EP 05812510 A EP05812510 A EP 05812510A EP 1791562 A4 EP1791562 A4 EP 1791562A4
Authority
EP
European Patent Office
Prior art keywords
vaccine
protein conjugates
derivatized polysaccharide
multivalent meningococcal
meningococcal derivatized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05812510A
Other languages
German (de)
French (fr)
Other versions
EP1791562A2 (en
Inventor
Robert P Ryall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Priority to EP10189369A priority Critical patent/EP2345422A1/en
Publication of EP1791562A2 publication Critical patent/EP1791562A2/en
Publication of EP1791562A4 publication Critical patent/EP1791562A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP05812510A 2004-09-21 2005-09-21 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine Withdrawn EP1791562A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10189369A EP2345422A1 (en) 2004-09-21 2005-09-21 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61212304P 2004-09-21 2004-09-21
PCT/US2005/033761 WO2006034320A2 (en) 2004-09-21 2005-09-21 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine

Publications (2)

Publication Number Publication Date
EP1791562A2 EP1791562A2 (en) 2007-06-06
EP1791562A4 true EP1791562A4 (en) 2008-07-09

Family

ID=36090637

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05812510A Withdrawn EP1791562A4 (en) 2004-09-21 2005-09-21 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
EP10189369A Withdrawn EP2345422A1 (en) 2004-09-21 2005-09-21 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10189369A Withdrawn EP2345422A1 (en) 2004-09-21 2005-09-21 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine

Country Status (10)

Country Link
EP (2) EP1791562A4 (en)
JP (2) JP2008513541A (en)
KR (1) KR20070095868A (en)
CN (1) CN101072586A (en)
AU (1) AU2005286798A1 (en)
BR (1) BRPI0516770A (en)
CA (1) CA2580693A1 (en)
IL (1) IL181951A0 (en)
MX (1) MX2007003292A (en)
WO (1) WO2006034320A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2351582A1 (en) * 2004-08-30 2011-08-03 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB2468803B (en) * 2005-05-19 2011-01-19 Exocyte Ltd Screening methods for bacterial killing
US9085610B2 (en) * 2009-07-31 2015-07-21 National Research Council Of Canada H. pylori lipopolysaccharide outer core epitope
ES2744471T3 (en) * 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Bactericidal antibody assays to assess immunogenesis and potency of meningococcal capsular saccharide vaccines
CN102462839B (en) * 2010-11-12 2016-03-30 北京生物制品研究所 polysaccharide conjugate vaccine and preparation method thereof
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
WO2014037585A1 (en) * 2012-09-10 2014-03-13 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
CN106046127A (en) * 2016-08-10 2016-10-26 成都生物制品研究所有限责任公司 Preparation method of diphtheria toxoid
SI3506935T1 (en) 2016-09-02 2024-06-28 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
CN106397537B (en) * 2016-10-13 2020-01-07 李红臣 Efficient and rapid purification and analysis method for polysaccharide-protein conjugate vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
WO2002058737A2 (en) * 2001-01-23 2002-08-01 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2003007985A2 (en) * 2001-06-20 2003-01-30 Chiron Srl. Capsular polysaccharide solubilisation and combination vaccines
WO2004103400A2 (en) * 2003-05-07 2004-12-02 Aventis Pasteur,Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5422427A (en) 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US20030035806A1 (en) * 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
PT1490409E (en) * 2002-03-26 2009-04-03 Novartis Vaccines & Diagnostic Modified saccharides having improved stability in water
EP2351582A1 (en) * 2004-08-30 2011-08-03 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
WO2002058737A2 (en) * 2001-01-23 2002-08-01 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2003007985A2 (en) * 2001-06-20 2003-01-30 Chiron Srl. Capsular polysaccharide solubilisation and combination vaccines
WO2004103400A2 (en) * 2003-05-07 2004-12-02 Aventis Pasteur,Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"DOSE ESCALATION, SAFETY AND IMMUNOGENICITY STUDY OF A TETRAVALENT MENINGOCOCCAL POLYSACCHARIDE DIPHTHERIA CONJUGATE VACCINE IN TODDLERS", PEDIATRIC INFECTIOUS DISEASE JOURNAL, WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 21, no. 10, 1 October 2002 (2002-10-01), pages 978/979, XP008015582, ISSN: 0891-3668 *
CAMPAGNE G ET AL: "SAFETY AND IMMUNOGENICITY OF THREE DOSES OF A NEISSERIA MENINGITIDIS A + C DIPHTHERIA CONJUGATE VACCINE IN INFANTS FROM NIGER", PEDIATRIC INFECTIOUS DISEASE JOURNAL, WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 19, no. 2, 1 February 2000 (2000-02-01), pages 144 - 150, XP008015581, ISSN: 0891-3668 *
CHIPPAUX J-P ET AL: "Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 25-26, 3 September 2004 (2004-09-03), pages 3303 - 3311, XP004526904, ISSN: 0264-410X *

Also Published As

Publication number Publication date
AU2005286798A1 (en) 2006-03-30
CN101072586A (en) 2007-11-14
JP2012140457A (en) 2012-07-26
WO2006034320A2 (en) 2006-03-30
WO2006034320A3 (en) 2006-09-28
MX2007003292A (en) 2007-09-07
IL181951A0 (en) 2007-07-04
CA2580693A1 (en) 2006-03-30
BRPI0516770A (en) 2008-09-23
JP2008513541A (en) 2008-05-01
KR20070095868A (en) 2007-10-01
EP1791562A2 (en) 2007-06-06
EP2345422A1 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
IL184154A0 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
HK1204574A1 (en) Multivalent meningococcal derivatized polysaccharide protein conjugates and corresponding vaccines
IL181951A0 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
HK1257962A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
HRP20190037T1 (en) Pneumococcal polysaccharide conjugate vaccine
HUS1600040I1 (en) Multivalent meningococcal polysaccharide-protein conjugate vaccine
ZA200904331B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
ZA200904619B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
IL181551A0 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
IL188222A (en) Immunogenic compositions and their use in immunizing an animal against tuberculosis
EP1814393A4 (en) Tolerogenic vaccine and method
EP1963522A4 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
IL181228A0 (en) Vlp-antigen conjugates and their uses as vaccines
ZA200708542B (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
AU2007203489A1 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
ZA200701667B (en) VLP-antigen conjugates and their use as vaccines
ZA200805347B (en) Pneumococcal polysaccharide conjugate vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070309

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080605

17Q First examination report despatched

Effective date: 20090714

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140401